Pinealon

Pinealon is classified as a short peptide bioregulator — a class of synthetic tripeptides conceptually derived from tissue-specific polypeptide preparations (in this case, the CNS-derived preparation Cortexin). Unlike classical receptor ligands, it carries no defined cell-surface or cytoplasmic receptor in the published literature. The proposed mechanism, advanced across reports from Khavinson and colleagues, involves direct interaction with nuclear DNA and possibly histones, positioning gene-transcription regulation as the operative level. Biophysical work by Silanteva et al. (2019) examined the interaction of the EDR tripeptide with double-stranded DNA using spectroscopy, NMR viscometry, and molecular-dynamics simulation, characterizing contacts primarily at guanine N7 and O6 atoms within the major groove, with divalent Mg²⁺ ions facilitating interaction through phosphate-backbone screening. Separately, docking analyses (Khavinson, Lin'kova, Tarnovskaya, 2016; Khavinson et al., 2021) proposed sequence-specific binding to promoter regions of candidate genes including TPH1, PPARA, PPARG, CASP3, SOD2, and GPX1. These biophysical and computational findings constitute the mechanistic framework; orthogonal wet-lab confirmation (ChIP, EMSA, structural biology) has not yet been reported outside modeling and limited biophysics.

The foundational in vitro dataset was reported by Khavinson et al. (2011), using rat cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells exposed to receptor-dependent (ouabain, homocysteine) and non-receptor (hydrogen peroxide) oxidative challenge. The study employed fluorescence-based ROS measurement, propidium-iodide exclusion for necrotic-cell assessment, ERK1/2 phosphorylation kinetics by western analysis, and flow-cytometric cell-cycle profiling. A related aging brain-cortex culture study (Khavinson et al., 2014) investigated serotonin expression alongside TPH1-promoter docking predictions in an age-context model, using the Glu-Asp-Arg tripeptide together with the structurally distinct Lys-Glu-Asp tripeptide.

Two experimental lines investigated Pinealon in synaptic-structure contexts. Kraskovskaya et al. (2017) used primary mouse hippocampal neurons exposed to amyloid synaptotoxicity and measured mushroom-spine density as the morphometric endpoint; a published correction was subsequently issued for that paper (2017). A study by Khavinson et al. (2021), conducted in the 5xFAD transgenic mouse line (B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas), examined CA1 secondary-dendrite spine density alongside molecular-docking predictions of candidate promoter binding; a 2025 published correction noted a figure-duplication error in that work, with the authors stating that the scientific conclusions were unaffected. A separate investigation (Khavinson et al., 2017) assessed striatal-neuron spine morphology in a Huntington's-disease mouse model; this study appeared in a non-PubMed-indexed venue.

Several rodent paradigms examined Pinealon alongside behavioral and neurochemical endpoints. Arutjunyan et al. (2012) used a prenatal maternal methionine-load protocol to induce hyperhomocysteinemia, then assessed offspring using the Morris water-maze and cerebellar-neuron oxidative-stress endpoints (ROS accumulation, propidium-iodide cell death). Hypoxia-model studies — including acute hypoxic hypoxia in aged rats — assessed antioxidant-enzyme activity, caspase-3, and Morris-maze acquisition and retention measures (Khavinson et al., 2014, 2015); one aged-rat study combined Pinealon with the polypeptide preparation Cortexin in both hypoxia and hypothermia conditions. Karantysh et al. (2020) examined Pinealon in the streptozotocin-diabetes rat model using Morris-maze retention and hippocampal NMDA-receptor subunit gene expression measured by real-time PCR as endpoints.

The published body of work is modest in size and substantially concentrated in research groups affiliated with the St. Petersburg Institute of Bioregulation and Gerontology, with V.Kh. Khavinson and N.S. Linkova as recurring authors across primary studies and reviews. Independent, non-affiliated replication is essentially absent from the indexed literature. Several primary papers and reviews appear in lower-impact or Russian-language journals, and one paper on striatal-neuron morphology was published in a non-PubMed-indexed venue. A widely circulated vendor PMID (23199282) is a documented misattribution — that identifier refers to an unrelated publication — and is therefore excluded from this reference set. No registered clinical trial was identified in ClinicalTrials.gov or the WHO International Clinical Trials Registry Platform for this compound. Human observations referenced in review articles and patent literature are non-indexed descriptions, not independently verified trial records, and are not listed as clinical citations here.